Compound EGFR Mutations Are Predominantly P-Loop and Alpha-C Helix Compressing Mutations With Increased Responsiveness to Second- Versus Third-Generation Tyrosine Kinase Inhibitors
Publication date: October 2026 Source: Journal of Thoracic Oncology, Volume 21, Issue 10 Author(s): Ximeng Liu, Moses Stamboulian, Maxime Borgeaud, Erjia Zhu, Caroline Weipert, Nicole Zhang, Monique B. Nilsson, Kaiwen Wang, Lingzhi Hong, Jinghao Wang, Benjamin B. Morris, Simon Heeke, Jacqulyne P. Robichaux, Courtney Lewis, Leylah Drusbosky, Hong Chen, Yan Yang, Junqin He, Li Cai, Jia Wu
Compound EGFR Mutations Are Predominantly P-Loop and Alpha-C Helix Compressing Mutations With Increased Responsiveness to Second- Versus Third-Generation Tyrosine Kinase Inhibitors. // Journal of Thoracic Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S1556086426004016?dgcid=rss_sd_all
Compound EGFR Mutations Are Predominantly P-Loop and Alpha-C Helix Compressing Mutations With Increased Responsiveness to Second- Versus Third-Generation Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology. https://www.sciencedirect.com/science/article/pii/S1556086426004016?dgcid=rss_sd_all
“Compound EGFR Mutations Are Predominantly P-Loop and Alpha-C Helix Compressing Mutations With Increased Responsiveness to Second- Versus Third-Generation Tyrosine Kinase Inhibitors.” Journal of Thoracic Oncology.
@article{article90015,
title = {Compound EGFR Mutations Are Predominantly P-Loop and Alpha-C Helix Compressing Mutations With Increased Responsiveness to Second- Versus Third-Generation Tyrosine Kinase Inhibitors},
journal = {Journal of Thoracic Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S1556086426004016?dgcid=rss_sd_all}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment